Technical Analysis for MTEM - Molecular Templates, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -0.62% | |
| Down 3 Days in a Row | Weakness | -0.62% | |
| 20 DMA Resistance | Bearish | -2.44% | |
| Wide Bands | Range Expansion | -2.44% | |
| Fell Below 20 DMA | Bearish | -4.19% |
| Alert | Time |
|---|---|
| Rose Above 20 DMA | about 16 hours ago |
| 60 Minute Opening Range Breakout | about 16 hours ago |
| Rose Above Previous Day's High | about 16 hours ago |
| Rose Above 10 DMA | about 16 hours ago |
| Outside Day | about 16 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Cancer Treatment Treatment Of Cancer Oncology Chemical Elements Lymphoma Oxygen Toxins Prodrugs Evofosfamide Prodrug Nitrogen Mustards
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Cancer Treatment Treatment Of Cancer Oncology Chemical Elements Lymphoma Oxygen Toxins Prodrugs Evofosfamide Prodrug Nitrogen Mustards
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.45 |
| 52 Week Low | 1.4 |
| Average Volume | 85,615 |
| 200-Day Moving Average | 4.85 |
| 50-Day Moving Average | 2.21 |
| 20-Day Moving Average | 1.65 |
| 10-Day Moving Average | 1.66 |
| Average True Range | 0.19 |
| RSI (14) | 37.89 |
| ADX | 24.94 |
| +DI | 15.20 |
| -DI | 20.26 |
| Chandelier Exit (Long, 3 ATRs) | 1.48 |
| Chandelier Exit (Short, 3 ATRs) | 1.96 |
| Upper Bollinger Bands | 1.89 |
| Lower Bollinger Band | 1.42 |
| Percent B (%b) | 0.38 |
| BandWidth | 28.21 |
| MACD Line | -0.15 |
| MACD Signal Line | -0.19 |
| MACD Histogram | 0.0435 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.89 | ||||
| Resistance 3 (R3) | 1.90 | 1.81 | 1.84 | ||
| Resistance 2 (R2) | 1.81 | 1.73 | 1.80 | 1.83 | |
| Resistance 1 (R1) | 1.70 | 1.69 | 1.70 | 1.70 | 1.81 |
| Pivot Point | 1.61 | 1.61 | 1.61 | 1.61 | 1.61 |
| Support 1 (S1) | 1.51 | 1.54 | 1.50 | 1.50 | 1.39 |
| Support 2 (S2) | 1.42 | 1.49 | 1.41 | 1.37 | |
| Support 3 (S3) | 1.31 | 1.42 | 1.36 | ||
| Support 4 (S4) | 1.31 |
